AI Science Tracker

Enterololin: AI helps clarify an antibiotic and its mechanism

MIT · 3 Oct 2025 · medicine

Discovery

MIT

Enterololin: AI helps clarify an antibiotic and its mechanism

An AI screen of over 10,000 molecules identified enterololin, and DiffDock predicted its binding to LolCDE within minutes, confirmed by resistant E. coli mutants, RNA-seq, and CRISPR. The mechanism was clarified in about six months versus 18–24 with traditional methods. In mice, in Crohn's-like inflammation models, healing was faster than with vancomycin. Early stage; no human testing.

Technology: Machine-learning screening and DiffDock

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Enterololin was tested in mouse Crohn's-like inflammation models against vancomycin, with resistant mutant sequencing, RNA-seq and CRISPR knockdown used to clarify its mechanism.
  • Still unknown: The source states it is early-stage development, no human data are reported, and clinical trials are not yet started.
  • AI role: DiffDock predicted binding of enterololin to the LolCDE complex within minutes, guiding lab experiments on the mechanism.

Evidence sources: https://news.mit.edu/2025/ai-maps-how-new-antibiotic-targets-gut-bacteria-1003 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41564-025-02142-0&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 28 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.